John leads single domain antibody discovery projects and biotherapeutic development at Inhibrx. He has been instrumental in developing Inhibrx’s multispecific antibody formats for conditional immune activation. John directs many aspects of research at Inhibrx including protein engineering, assay development, and new technologies. Prior to joining Inhibrx in 2010, John completed his postdoctoral training in Jack Dixonâ€™s laboratory in the Department of Pharmacology at UCSD. John received his Ph.D. from the UCSD Biomedical Sciences Program, performing his thesis research in the laboratory of Guy Salvesen at the Sanford-Burnham-Prebys Medical Discover Institute.